Literature DB >> 1740660

Targeting autoantigen to B cells prevents the induction of a cell-mediated autoimmune disease in rats.

M J Day1, A G Tse, M Puklavec, S J Simmonds, D W Mason.   

Abstract

Immunization protocols that induce high levels of delayed-type hypersensitivity are often associated with low levels of antibody production, whereas alternative immunization strategies can produce the opposite effect. This reciprocal relationship appears to depend, at least in part, on the fact that T cell-derived lymphokines that are predominantly involved in one type of response inhibit the development of those T cells that promote the alternative one. Such a regulatory mechanism is likely to be bistable in that whenever one form of response is established, spontaneous development of the alternative one will be inhibited. We have applied this concept to the control of a cell-mediated autoimmune disease in rats. By covalently linking the autoantigen to anti-IgD antibody, we have targeted it to B cells for presentation to antigen-specific T cells. This form of presentation favors antibody production and may be expected to antagonize the cell-mediated disease-inducing response to the same antigen. To test this hypothesis, use was made of the fact that experimental allergic encephalomyelitis (EAE), when induced with the encephalitogenic peptide of guinea pig myelin basic protein, is purely a cell-mediated disease. The experiments show that Lewis rats, immunized with the peptide in its encephalitogenic form, were protected from disease when simultaneously injected with the peptide coupled to anti-IgD monoclonal antibodies. Control experiments showed that neither peptide nor anti-IgD alone were protective, and the peptide covalently coupled to irrelevant antibodies also failed to protect. Spleen cells from animals protected from disease by the anti-IgD-peptide conjugate, when activated in vitro with the encephalitogen, were able to transfer EAE to naive recipients. The results demonstrate that a cell-mediated immune response can be controlled by appropriate targeting of the specific antigen without inducing T cell anergy and suggest a potential strategy for preventing autoimmune diseases that are essentially cell-mediated in type.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1740660      PMCID: PMC2119141          DOI: 10.1084/jem.175.3.655

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  27 in total

Review 1.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

2.  Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies.

Authors:  S Mjaaland; S Fossum
Journal:  Eur J Immunol       Date:  1990-07       Impact factor: 5.532

3.  Purification of human C3b inactivator by monoclonal-antibody affinity chromatography.

Authors:  L Hsiung; A N Barclay; M R Brandon; E Sim; R R Porter
Journal:  Biochem J       Date:  1982-04-01       Impact factor: 3.857

4.  The localization of populations of lymphocytes defined by monoclonal antibodies in rat lymphoid tissues.

Authors:  A N Barclay
Journal:  Immunology       Date:  1981-04       Impact factor: 7.397

5.  In vivo effects of antibodies to immune response gene products: prevention of experimental allergic encephalitis.

Authors:  L Steinman; J T Rosenbaum; S Sriram; H O McDevitt
Journal:  Proc Natl Acad Sci U S A       Date:  1981-11       Impact factor: 11.205

6.  Effects of experimental allergic encephalomyelitis on thymus and adrenal: relation to remission and relapse.

Authors:  S Levine; R Sowinski; B Steinetz
Journal:  Proc Soc Exp Biol Med       Date:  1980-11

7.  Expression of the bcl-2 oncogene protein is not specific for the 14;18 chromosomal translocation.

Authors:  F Pezzella; A G Tse; J L Cordell; K A Pulford; K C Gatter; D Y Mason
Journal:  Am J Pathol       Date:  1990-08       Impact factor: 4.307

8.  Contrasting effects of glucocorticoids on the capacity of T cells to produce the growth factors interleukin 2 and interleukin 4.

Authors:  R A Daynes; B A Araneo
Journal:  Eur J Immunol       Date:  1989-12       Impact factor: 5.532

9.  Experimental allergic encephalomyelitis: successful treatment in vivo with a monoclonal antibody that recognizes T helper cells.

Authors:  S W Brostoff; D W Mason
Journal:  J Immunol       Date:  1984-10       Impact factor: 5.422

10.  Suppression of experimental allergic encephalomyelitis in guinea/pigs by liposome-associated human myelin basic protein.

Authors:  G H Strejan; D H Percy; J St Louis; D Surlan; D W Paty
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

View more
  18 in total

Review 1.  Systemic immunomodulation of autoimmune disease using MHC-derived recombinant TCR ligands.

Authors:  Gregory G Burrows
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

Review 2.  Modulation of the immune response with T-cell epitopes: the ultimate goal for specific immunotherapy of autoimmune disease.

Authors:  P J Fairchild; C J Thorpe; P J Travers; D C Wraith
Journal:  Immunology       Date:  1994-04       Impact factor: 7.397

3.  Selective development of T helper (Th)2 cells induced by continuous administration of low dose soluble proteins to normal and beta(2)-microglobulin-deficient BALB/c mice.

Authors:  J C Guery; F Galbiati; S Smiroldo; L Adorini
Journal:  J Exp Med       Date:  1996-02-01       Impact factor: 14.307

Review 4.  Antigen-specific immunotherapy of autoimmune disease: a commentary.

Authors:  D C Wraith
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

5.  B cells limit epitope spreading and reduce severity of EAE induced with PLP peptide in BALB/c mice.

Authors:  Jeri-Anne Lyons; Michael J Ramsbottom; Robert J Mikesell; Anne H Cross
Journal:  J Autoimmun       Date:  2008-06-09       Impact factor: 7.094

6.  Transplantation tolerance is unrelated to superantigen-dependent deletion and anergy.

Authors:  J Salaün; A Bandeira; I Khazaal; O Burlen-Defranoux; V Thomas-Vaslin; M Coltey; N M Le Douarin; A Coutinho
Journal:  Proc Natl Acad Sci U S A       Date:  1992-11-01       Impact factor: 11.205

7.  Intranasal administration of retinal antigens suppresses retinal antigen-induced experimental autoimmune uveoretinitis.

Authors:  A D Dick; Y F Cheng; J Liversidge; J V Forrester
Journal:  Immunology       Date:  1994-08       Impact factor: 7.397

8.  Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro.

Authors:  G Baier; G Baier-Bitterlich; D J Looney; A Altman
Journal:  J Virol       Date:  1995-04       Impact factor: 5.103

9.  Cellular mRNA expression of interferon-gamma, IL-4 and transforming growth factor-beta (TGF-beta) by rat mononuclear cells stimulated with peripheral nerve myelin antigens in experimental allergic neuritis.

Authors:  J Zhu; E Mix; T Olsson; H Link
Journal:  Clin Exp Immunol       Date:  1994-11       Impact factor: 4.330

10.  Differential binding of Escherichia coli enterotoxins LT-IIa and LT-IIb and of cholera toxin elicits differences in apoptosis, proliferation, and activation of lymphoid cells.

Authors:  Sergio Arce; Hesham F Nawar; Michael W Russell; Terry D Connell
Journal:  Infect Immun       Date:  2005-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.